AU4453301A - Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis - Google Patents

Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis

Info

Publication number
AU4453301A
AU4453301A AU44533/01A AU4453301A AU4453301A AU 4453301 A AU4453301 A AU 4453301A AU 44533/01 A AU44533/01 A AU 44533/01A AU 4453301 A AU4453301 A AU 4453301A AU 4453301 A AU4453301 A AU 4453301A
Authority
AU
Australia
Prior art keywords
spirolaxin
treatment
diseases associated
abnormal angiogenesis
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44533/01A
Inventor
Sergio Penco
Claudio Pisano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU4453301A publication Critical patent/AU4453301A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU44533/01A 2000-03-13 2001-03-07 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis Abandoned AU4453301A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2000RM000129A IT1317001B1 (en) 2000-03-13 2000-03-13 USE OF SPIROLAXIN FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH AN ALTERED ANGIOGENESIS.
ITRM200A000129 2000-03-13
PCT/IT2001/000113 WO2001068070A2 (en) 2000-03-13 2001-03-07 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis

Publications (1)

Publication Number Publication Date
AU4453301A true AU4453301A (en) 2001-09-24

Family

ID=11454527

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44533/01A Abandoned AU4453301A (en) 2000-03-13 2001-03-07 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis

Country Status (3)

Country Link
AU (1) AU4453301A (en)
IT (1) IT1317001B1 (en)
WO (1) WO2001068070A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010136A1 (en) * 2001-03-16 2002-09-16 Sigma Tau Ind Farmaceuti USEFUL COMPOUNDS FOR THE TREATMENT OF DISEASES THAT RESPOND TO THE ACTIVATION OF THE PPAR-GAMMA RECEPTOR.
ITMI20041279A1 (en) * 2004-06-24 2004-09-24 Pharmaproducts Uk Ltd USE OF TRIFLUOROACETATE CALCIUM FOR THE PREPARATION OF ANTI-ANGIOGENETIC EFFECT MEDICATIONS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174710B1 (en) * 1994-08-09 2001-01-16 Pfizer Inc. Spirolaxine derivatives for treating gastrobuodenal diseases
JPH107557A (en) * 1996-06-17 1998-01-13 Banyu Pharmaceut Co Ltd Antitumor substance spirolaxine
AU751283B2 (en) * 1998-07-14 2002-08-08 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin

Also Published As

Publication number Publication date
WO2001068070A8 (en) 2001-11-08
ITRM20000129A1 (en) 2001-09-13
WO2001068070A2 (en) 2001-09-20
WO2001068070A3 (en) 2002-04-18
ITRM20000129A0 (en) 2000-03-13
IT1317001B1 (en) 2003-05-26

Similar Documents

Publication Publication Date Title
MXPA03002814A (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases.
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
HK1061021A1 (en) Pyrazole derivatives for the treatment of viral diseases.
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU6910600A (en) Methods for the treatment of mental disorders
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
GB0004531D0 (en) The treatment of respiratory diseases
AU2001293891A1 (en) New combination for the treatment of asthma
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2002333510A1 (en) Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
AU2002359635A1 (en) Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
AU4453301A (en) Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
AU3064800A (en) The therapeutic use of r-warfarin as anticoagulant
AU1405001A (en) Treatment of diseases
AU2002221566A1 (en) Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
MXPA03004454A (en) Imidazolone derivatives for the treatment of viral diseases.
AU3501100A (en) Synergistic combination for treatment of viral-mediated diseases
AU2001262520A1 (en) Combined preparation for the treatment of neoplasic diseases
AU2001228863A1 (en) Remedies for ophthalmic diseases
AU3071899A (en) Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase